Draft:Pediatric Endocrine Society
 | Draft article not currently submitted for review.
This is a draft Articles for creation (AfC) submission. It is not currently pending review. While there are no deadlines, abandoned drafts may be deleted after six months. To edit the draft click on the "Edit" tab at the top of the window. To be accepted, a draft should:
It is strongly discouraged to write about yourself, your business or employer. If you do so, you must declare it. Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Last edited by Diannaa (talk | contribs) 6 days ago. (Update) |
The Pediatric Endocrine Society (PES) is a professional medical association.[1] It was founded in 1972 as the Lawson Wilkins Pediatric Endocrine Society.[2] The organization celebrated turning 50 in 2022.[3]
Thomas Carpenter, MD is the current president[4] (2024). The organization is based in Washington D.C. Pediatric Endocrine Society (PES) 2024 Annual Meeting is taking place May 2-5, 2024, in Chicago, IL.[5] The society has a membership count of between 1500-1600 members.[6]
In August 2015, the Pediatric Endocrine Society released recommendations for Evaluation and Management of Persistent Hypoglycemia in Neonates, Infants, and Children.[7]
In April 2019, PES responded to a request by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) with endocrine funding priorities; obesity and diabetes were at the top of the list.[8]
In 2021, PES offered updated recommendations for use of growth-promoting hormone therapy and related medications in children. The Guidelines for Growth Hormone and Insulin-Like Growth Factor-1 Treatment in Children and Adolescents were updated from 2003 and reflect the continuing controversy over how to diagnose, categorize and treat growth failure in children.[9] The guideline was developed following the GRADE approach (Grading of Recommendations, Assessment, Development, and Evaluation).[10]
In April 2021, PES released a position statement in support of Gender Affirming Care (GAC).[11] In it it states, "Puberty suppression and/or gender-affirming hormone therapy is recommended within this evidence-based approach on a case-by-case basis as medically necessary and is potentially lifesaving." This position is at odds with the position of England's National Health Service (NHS) which maintains that evidence for puberty blockers and hormone treatment for gender transition wholly is inadequate, [12] and has decided to stop routine prescribing of puberty blockers.[13]
In February 2023 Nicole Glaser, a pediatric endocrinologist from UC Davis received the Senior Researcher Award from the Pediatric Endocrine Society.[14]
In May 2023, PES held its annual meeting in San Diego, CA. Abstracts included the following topics: Adrenal, Bone and Mineral, Diabetes – type 1, Diabetes – type 2, Equity, Diversity, and Inclusion, Fetal and Neonatal Endocrinology and Metabolism, Genetic Syndromes, Growth and GH/IGF Axis, Lipids, Multisystem Endocrine Disorders, Neuroendocrinology/Hypothalamic Pituitary, Obesity, PCOS, Puberty, Quality Improvement/Education, Sex Differentiation/Gonads and DSD, Thyroid, Transgender Health and Transition to Adult Care.[15]
References[edit]
- ^ "Strategic Plan - Pediatric Endocrine Society". 2020-05-15. Retrieved 2024-04-25.
- ^ Oberfield, Sharon E.; Rogol, Alan D.; Miller, Walter L. (2022). "A Brief History of the Pediatric Endocrine Society (PES)". Hormone Research in Paediatrics. 95 (6): 510–514. doi:10.1159/000526439. ISSN 1663-2826. PMID 36446318.
- ^ "Celebrating 50 Years of the Pediatric Endocrine Society (PES): Histories of Pediatric Endocrine Topics. | Department of Pediatrics". pediatrics.ucsf.edu. Retrieved 2024-04-30.
- ^ "Thomas Carpenter, MD - Pediatric Endocrine Society". 2022-05-03. Retrieved 2024-04-25.
- ^ "Spruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting". www.businesswire.com. 2024-04-22. Retrieved 2024-04-29.
- ^ georgeb@degnon.org (2024-04-23). "April 2024 President's Letter - Pediatric Endocrine Society". Retrieved 2024-04-30.
- ^ Thornton, Paul S.; Stanley, Charles A.; De Leon, Diva D.; Harris, Deborah; Haymond, Morey W.; Hussain, Khalid; Levitsky, Lynne L.; Murad, Mohammad H.; Rozance, Paul J.; Simmons, Rebecca A.; Sperling, Mark A.; Weinstein, David A.; White, Neil H.; Wolfsdorf, Joseph I.; Pediatric Endocrine Society (August 2015). "Recommendations from the Pediatric Endocrine Society for Evaluation and Management of Persistent Hypoglycemia in Neonates, Infants, and Children". The Journal of Pediatrics. 167 (2): 238–245. doi:10.1016/j.jpeds.2015.03.057. ISSN 1097-6833. PMID 25957977.
- ^ Singer, Kanakadurga; Katz, Michelle L.; Mittelman, Steven D. (August 2019). "Proposed endocrine funding priorities for the NICHD strategic plan: expert opinion from the Pediatric Endocrine Society". Pediatric Research. 86 (2): 141–143. doi:10.1038/s41390-019-0401-0. ISSN 1530-0447.
- ^ "Idiopathic Short Stature Addressed in Guidelines". www.medcentral.com. 2021-06-28. Retrieved 2024-04-25.
- ^ Grimberg, Adda; DiVall, Sara A.; Polychronakos, Constantin; Allen, David B.; Cohen, Laurie E.; Quintos, Jose Bernardo; Rossi, Wilma C.; Feudtner, Chris; Murad, Mohammad Hassan; on behalf of the Drug and Therapeutics Committee and Ethics Committee of the Pediatric Endocrine Society (2016-11-25). "Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency". Hormone Research in Paediatrics. 86 (6): 361–397. doi:10.1159/000452150. ISSN 1663-2818.
- ^ "Medical Association Statements in Support of Health Care for Transgender People and Youth | GLAAD". glaad.org. 2023-06-21. Retrieved 2024-04-27.
- ^ "Evidence for puberty blockers and hormone treatment for gender transition wholly inadequate | BMJ". Retrieved 2024-04-30.
- ^ O’Dowd, Adrian (2024-03-14). "NHS services in England are told to stop routine prescribing of puberty blockers". BMJ. 384: q660. doi:10.1136/bmj.q660. ISSN 1756-1833. PMID 38485137.
- ^ Tomiyoshi, Tricia. "Pediatric endocrinologist receives senior researcher award". UC Davis Health. Retrieved 2024-04-25.
- ^ "Abstracts of the 2023 Pediatric Endocrine Society (PES) Annual Meeting' to Hormone Research in Paediatrics". Hormone Research in Paediatrics. 96 (Suppl. 3): 1–399. 2023-07-26. doi:10.1159/000531602. ISSN 1663-2818.